平滑肌細(xì)胞是多數(shù)重要?jiǎng)用}疾病的靶細(xì)胞。血管SMC的生長(zhǎng)潛力是原發(fā)血管病發(fā)展中至關(guān)重要的異常因素。*新研究表明SMC表達(dá)的鈣通道，其表面表達(dá)的ICAM-1和VCAM-1，均參與了血管壁的炎癥反應(yīng)，并與血管疾病的進(jìn)展和穩(wěn)定有關(guān)。慢性肺組織缺氧能造成血管重塑，肺動(dòng)脈平滑肌增生，*終導(dǎo)致肺動(dòng)脈高壓。人血管平滑肌的體外培養(yǎng)可作為血管研究模型，為血管疾病的治療和藥理學(xué)研究提供信息，發(fā)揮重要作用。
人肺動(dòng)脈平滑肌細(xì)胞提取于人肺動(dòng)脈組織，二代凍存。每管含有細(xì)胞數(shù)>5×10^5 cells/ml，此細(xì)胞通過(guò)對(duì)alpha-SMA和Desmin免疫熒光染色驗(yàn)證，經(jīng)測(cè)試不含有HIV-1、HBV、HCV、支原體、細(xì)菌、酵母和真菌。細(xì)胞可以達(dá)到15倍增。
推薦培養(yǎng)基：平滑肌細(xì)胞培養(yǎng)基 (SMCM, Cat. #1101)
|
貨號(hào)
|
3110
|
|
產(chǎn)地
|
美國(guó)
|
|
縮寫(xiě)
|
HPASMC
|
|
規(guī)格
|
5 x 10^5 /1ml
|
|
用途
|
科研
|
|
儲(chǔ)存
|
液氮
|
|
運(yùn)輸
|
干冰
|
|
關(guān)鍵字
|
人肺動(dòng)脈平滑肌細(xì)胞 HPASMC 人肺動(dòng)脈平滑肌細(xì)胞 HPASMC 人肺動(dòng)脈平滑肌細(xì)胞 HPASMC 人肺動(dòng)脈平滑肌細(xì)胞 HPASMC 人肺動(dòng)脈平滑肌細(xì)胞 HPASMC 人肺動(dòng)脈平滑肌細(xì)胞 HPASMC 人肺動(dòng)脈平滑肌細(xì)胞 HPASMC 人肺動(dòng)脈平滑肌細(xì)胞 HPASMC
|
公司簡(jiǎn)介
|
合肥星肽生物科技有限公司作為專業(yè)的ScienCell中國(guó)代理商，專業(yè)經(jīng)營(yíng)實(shí)驗(yàn)室科研用原代細(xì)胞、原代細(xì)胞專用培養(yǎng)基、原代細(xì)胞無(wú)血清培養(yǎng)基、干細(xì)胞、干細(xì)胞培養(yǎng)基、干細(xì)胞無(wú)血清培養(yǎng)基的研究和開(kāi)發(fā)。合肥星肽生物科技有限公司始終致力于為客戶提供可靠的研究材料以及方便快捷的服務(wù)，對(duì)購(gòu)買項(xiàng)目的前期資料提供,中期合同保證,后期貨物跟蹤到*終售后的確保項(xiàng)目準(zhǔn)確到位，都有相關(guān)專業(yè)人士進(jìn)行維護(hù),確保您在合肥合肥星肽生物科技有限公司公司獲得*上等服務(wù)！
|
|
聯(lián)系方式
|
何經(jīng)理，合肥星肽生物科技有限公司，Tel：0551-63802898 400-8702-898，
E-mail：info@qingbio.com http://www.dyjy66.com QQ:514713116
|
1.) Wang HL, Peng LP, Chen WJ, Tang SH, Sun BZ, Wang CL, Huang R, Xu ZJ, Lei WF. (2014) 'HMGB1 enhances smooth muscle cell proliferation and migration in pulmonary artery remodeling.'
2.) Ibrahim YF, Wong CM, Pavlickova L, Liu L, Trasar L, Bansal G, Suzuki YJ. (2014) 'Mechanism of the Susceptibility of Remodeled Pulmonary Vessels to Drug?Induced Cell Killing.'
3.) Wang G, Liu X, Meng L, Liu S, Wang L, Li J, Cui C, Meng J, Hu S, Wei Y. (2014) 'Up-Regulated Lipocalin-2 in Pulmonary Hypertension Involving in Pulmonary Artery SMC Resistance to Apoptosis.'
4.) Ibrahim YF, Wong CM, Pavlickova L, Liu L, Trasar L, Bansal G, Suzuki YJ. (2014) "Mechanism of the Susceptibility of Remodeled Pulmonary Vessels to Drug?Induced Cell Killing." J Am Heart Assoc. 3: e000520.
5.) Wang G, Liu X, Meng L, Liu S, Wang L, Li J, Cui C, Meng J, Hu S, Wei Y. (2014) "Up-Regulated Lipocalin-2 in Pulmonary Hypertension Involving in Pulmonary Artery SMC Resistance to Apoptosis." Int j biol sci. 10: 798-806.
6.) Wang HL, Peng LP, Chen WJ, Tang SH, Sun BZ, Wang CL, Huang R, Xu ZJ, Lei WF. (2014) "HMGB1 enhances smooth muscle cell proliferation and migration in pulmonary artery remodeling." Int j clinexppathol. 7: 3836-44.
7.) Zha WJ, Qian Y, Shen Y, Du Q, Chen FF, Wu ZZ, Li X, Huang M. (2013) "Galangin Abrogates Ovalbumin-Induced Airway Inflammation via Negative Regulation of NF-?B."Evid Based Complement Alternat Med. 2013:767689.
8.) Wang G, Zhang Z, Xu Z, Yin H, Bai L, Ma Z, Decoster MA, Qian G, Wu G. (2010) "Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxia." Biochim Biophys Acta. 1803: 1359-67.
9.) de Frutos S, Nitta CH, Caldwell E, Friedman J, Gonz?lez Bosc LV. (2009) "Regulation of soluble guanylyl cyclase-alpha1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR." Am J Physiol Lung Cell Mol Physiol. 297: L475-86.
10.) de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M. (2009) "Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways." J Cell Biol.184: 83-99.
11.) Wang Z, Yuan Z, Jin L. (2008) "Gene delivery into hepatocytes with the preS/liposome/DNA system." Biotechnol J. 3: 1286-95.
12.) Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. (2007) "Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand." Proc Natl Acad Sci USA. 104: 5163-8.
